GleamWall
中文EN

KOD Kodiak Sciences Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1468748 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-13.5%
TTM EPS YoY1.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,360.9%
ROA-115.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets94.0%
Debt / equity0.00x
Current ratio1.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-36.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$182.37M$126.09M
SG&A expense$52.02M$60.75M
Operating income-$234.39M-$186.85M
Interest expense$0$0
Pretax income-$229.91M-$176.19M
Income tax$52,000$20,000
Net income-$229.97M-$176.21M
EBITDA-$216.06M-$168.14M
EPS (basic)-4.32-3.35
EPS (diluted)-4.32-3.35
Weighted avg. shares (diluted)53.21M52.58M
Balance sheet
Cash & equivalents$209.86M$168.07M
Current assets$214.82M$171.94M
PP&E, net$85.26M$102.22M
Total assets$351.53M$335.58M
Current liabilities$45.53M$25.57M
Total liabilities$194.15M$185.29M
Shareholders' equity$157.38M$150.29M
Shares outstanding61.76M52.73M
Cash flow statement
Operating cash flow-$136.01M-$117.32M
Capital expenditure$506,000$375,000
Free cash flow-$136.51M-$117.69M
Investing cash flow-$506,000-$755,000
Financing cash flow$178.30M$501,000
Depreciation & amortization$18.33M$18.71M
Stock-based compensation$58.86M$60.21M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.